At a Glance
- Licensor: GSK
- Partner: SiranBio (China)
- Deal value: $40M upfront + up to $960M milestones
- Focus area: Metabolic/kidney disease siRNAs
- Next steps: Phase 1/IND handoff to GSK
What happened?
GSK signed a licensing agreement with Chinese biotech SiranBio for two siRNA candidates targeting metabolic diseases, particularly inflammation-driven kidney disorders. GSK pays $40 million upfront and up to $960 million in milestones plus royalties for global rights.
Why does it matter?
SiRNA enables precise gene silencing for undruggable targets; GSK’s deal expands immunology pipeline with first-in-class oligos for kidney disease, aligning with respiratory/inflammation focus. Builds on GSK’s siRNA investments amid modality’s growth.
Who’s behind it?
SiranBio advances one to Phase 1 in China, IND-enabling for second; GSK takes global development post-handoff. Kaivan Khavandi (GSK R&I head) highlighted platform synergy.
How was it achieved?
SiranBio completes early studies; GSK handles global clinical/regulatory/commercial. Complements GSK’s Empirico COPD siRNA and Wave ASO deals.
What’s next?
GSK advances post-Phase 1/IND; potential first-in-class kidney therapies. SiranBio gains royalties, validation.
What are people saying?
Kaivan Khavandi, GSK: “Potential first-in-class… significant opportunity in multiple kidney diseases.”